Myeloproliferative neoplasms (MPNs) are characterized by overproduction of mature functional blood cells and are often associated with an acquired genetic mutation of Janus Kinase 2 V617F . The etiology of MPNs remains unknown. The aim of this article was to review and collate all known published data investigating environmental and lifestyle factors associated with MPNs. Medline, Embase, PubMed, Cochrane, and Web of Science were systematically searched using terms for MPNs and observational study designs to identify studies investigating the risk factors for MPNs published before March 2010. Of 9,156 articles identified, 19 met the selection criteria. Although the studies exhibited heterogeneity, in case definitions, study design, and risk factors investigated, several themes emerged. A strong association was found with Jewish descent, and with a family history of MPNs. Autoimmune conditions, specifically Crohn's disease, were more common in patients with MPNs. Certain occupational groups were significantly associated with MPNs including occupations with potential exposure to benzene and/or petroleum. Blood donation was associated with an increased risk of polycythemia vera specifically. The vast heterogeneity in studies identified as part of this review suggests that large scale systematic assessment of etiological factors associated with MPNs is warranted. Am. J. Hematol. 87:175-182, 2012. V V C 2011 Wiley Periodicals, Inc.
IntroductionMyeloproliferative neoplasms (MPNs) are a group of hematopoietic malignancies resulting from a transformed hematopoietic progenitor cell. They are characterized by overproduction of mature functional blood cells. MPNs were historically termed myeloproliferative disorders and have undergone numerous amendments in classification. The 2008 World Health Organisation MPN classification groups a number of related disorders including the classic MPNs polycythemia vera (PV), essential thrombocythemia (ET), and primary/idiopathic myelofibrosis (PMF) [1] which will be the focus of this review. Reported incidence rates vary from 0.02 to 2.8 per 100,000 persons [2]. However, incidence rates are not well characterized and half of all patients are asymptomatic at diagnosis [1]. PV and ET are indolent neoplasms with better prognosis (88% and 92% 3-year survival, respectively) compared to PMF which has a 63% 3-year survival in the United States [3].An acquired genetic mutation of Janus kinase 2 (JAK2) V617F is present in the majority of PV patients and in approximately half of patients with ET and PMF [4]. A recent study investigating JAK2 V617F mutations in 10,507 participants of the Copenhagen City Heart Study reported an incidence rate of 171 per 100,000 persons [5]. These participants had higher overall morbidity and mortality than those who were JAK2 V617F negative; however, 28% did not develop any malignancy during the 17.6-year follow-up [5] [12]. The population attributable risk of 46/1 JAK2 in PV patients has been estimated at 28%, explaining approximately 50% of the increased risk of...